When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials ...

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

'But it got worse. The fatigue – the same fatigue I'd ironically gone to the GP for in the first place – got worse. I ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Groundbreaking weight-loss drugs like Ozempic and Wegovy do not address the problem fueling the global obesity crisis: our ...